fda compounding semaglutide enforcement october 2025 news 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these New project announcement: HHS‑OIG is

[2] Novo Nordisk and Eli Lilly Globally, the GLP-1 medications market is controlled by two major pharmaceutical companies, U.S.-based Eli Lilly and Denmark-based Novo Nordisk

According to the Centers for Disease Control and Prevention, approximately 74% of adults in the United States are overweight, which includes an estimated 33% of men being obese

When you burp and this gas escapes from your stomach and esophagus, you experience both the smell (which others around you might notice) and the taste (which only you experience, thankfully)

Medicare can only cover GLP-1 medications if you have diabetes

FDA-Approved GLP-1s for Weight Loss Semaglutide (Wegovy): Approved for obesity treatment, can lead to weight loss exceeding 15-20% of body weight

Participants receiving Retatrutide at the 12 mg dose achieved average weight loss of 24.2% over 48 weeks